Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies by Chicheportiche, Yves et al.
Research article
Proinflammatory activity of TWEAK on human dermal fibroblasts
and synoviocytes: blocking and enhancing effects of anti-TWEAK
monoclonal antibodies
Yves Chicheportiche, Rachel Chicheportiche*, Irene Sizing†, Jeff Thompson†, 
Christopher B Benjamin†, Christine Ambrose† and Jean-Michel Dayer*
CyGen, Carouge, Switzerland
*Division of Immunology and Allergy, University Hospital, Geneva, Switzerland
†Biogen Inc., Cambridge, Massachusetts, USA
Correspondence: Jean-Michel Dayer, MD, Division of Immunology and Allergy, University Hospital, 1211 Geneva 14, Switzerland. 
Tel: +41 22 3729409; fax +41 22 3729418; e-mail: Jean-Michel.Dayer@hcuge.ch
Introduction
Interleukin-1 (IL-1) and tumour necrosis factor (TNF),
mainly produced by macrophages, are among the princi-
pal cytokines occurring in acute and chronic inflammatory
diseases. They act on a large number of target cells by
inducing, for instance, the expression of cytokines,
chemokines, cytokine receptors, prostanoids, adhesion
molecules and matrix metalloproteinases (MMPs). Under
the control of T cells and macrophages, synoviocytes con-
tribute to the destructive inflammatory process of the artic-
ular structures in chronic arthritic diseases [1–4]. This
type of cellular interaction is not only mediated by soluble
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factors but also by direct contact between stimulated T
cells, inducing macrophages to produce large amounts of
TNF and IL-1 [5,6]. These cytokines induce the production
of MMP-1, MMP-3 and inflammatory molecules such as
prostaglandin E2 (PGE2), leading to the degradation of the
extracellular matrix and the resorption of the mineral phase
of the bone [1–4]. In addition, IL-1 and TNF induce the
production of IL-6 and chemokines (e.g. IL-8, macrophage
chemoattractant protein-1 [MCP-1]); IL-6 is mainly
involved in activating B cells and MCP-1 is involved in
recruiting inflammatory cells [7,8].
Three lines of results point to TNF and IL-1 as principal
players in rheumatoid arthritis and probably also in other
chronic inflammatory diseases. Studies have shown that
patients suffering from joint inflammation have higher
serum and/or synovial levels of TNF and IL-1 [3,4,7,9].
Another group has reported that transgenic mice secret-
ing large amounts of TNF develop arthritis and joint
destruction [10]. Furthermore, natural inhibitors of TNF
and IL-1 that are soluble receptors or antagonists (i.e.
TNFsR, IL-1sRII and IL-1Ra) [11–13] and blocking anti-
bodies to TNF and IL-1 are able to limit joint inflammation,
pain and bone erosion in patients with rheumatoid arthritis
[3,14–16]. Despite impressive clinical results with anti-
TNF therapy, however, not all patients respond to such
treatment and, in many, joint destruction continues to
progress [17–18]. This could imply that other cytokines, in
particular members of the TNF family, may play an addi-
tional role.
TNF-like weak inducer of apoptosis (TWEAK ) is another
member of the TNF superfamily which currently includes
more than 15 proteins involved in inflammation, cell differ-
entiation, cell death and immune organ formation [19]. It is
a secreted protein with cytotoxic and proinflammatory
activities [20–25]. TWEAK was also shown to act as a
growth factor by inducing the proliferation of endothelial
cells [26]. As is the case for the other members of the
TNF family [27–31], the active form of TWEAK is a trimer
[20]. In this study, recombinant, soluble TWEAK and anti-
TWEAK mAbs were tested for their ability to induce or
block proinflammatory responses in human dermal fibrob-
lasts and synoviocytes.
Materials and methods
Dermal fibroblasts and synoviocytes
To isolate human dermal fibroblasts and synoviocytes,
respectively, foreskin of normal donors and surgical speci-
mens from patients with rheumatoid arthritis and advanced
osteoarthritis were subjected to protease treatment as
already described [1,2,6]. Synoviocytes were used from
the third to the ninth passage. The cells were cultured in
Dulbecco’s modified Eagle’s medium (Life Technologies,
Paisley, UK) supplemented with 10% FCS (Seromed/
Biochrom KG, Berlin, Germany), 50 µg/ml streptomycin,
50 IU/ml penicillin and 2 mM L-glutamine, at 37°C in 5%
CO2. The cells were seeded at 2 × 104 cells/well into 96-
well flat-bottom plates (Costar, Acton, MA, USA) and
maintained for 48 hours before testing. Fresh medium
(200 µl) either alone or together with cytokines and/or
antibodies was then added for 72 hours, in the presence
of 2 µg/ml of polymyxin B (Sigma, St Louis, MO, USA).
The conditioned media were collected and stored at
–20°C until further analysis.
For blockade experiments, antibodies were preincubated
in Eppendorf tubes at a final concentration of 10–7 M with
cytokines or medium alone for 30 min at 37°C, and 200 µl
of the mixtures were then added to the cells.
For mRNA experiments, 2 × 106 cells were plated in
culture plates (Falcon, Becton Dickinson, Heidelberg,
Germany) in the absence or presence of cytokines and/or
antibodies in a total volume of 5 ml of medium containing
2 µg/ml of polymyxin B for the indicated time.
Recombinant proteins and monoclonal antibodies
TNF and IL-1β were from Biogen (Cambridge, MA, USA).
Recombinant soluble human TWEAK contains an NH2-ter-
minal myc tag followed by amino acid residues
Ala106–His249 of hTWEAK (GenBank accession #
AF030099). hTWEAK was expressed by the yeast Pichia
pastoris (Invitrogen, Groningen, The Netherlands) and
purified by conventional methods. Monoclonal antibody to
human TNF (D2E7, LU 200134) was from Knoll (BASF
Pharma, Ludwigshafen, Germany). Hamster monoclonal
antibodies to hTWEAK were prepared using conventional
methods by injecting Armenian hamsters intraperitoneally
with recombinant soluble hTWEAK in complete Freund
adjuvant, followed by intraperitoneal booster in incomplete
Freund adjuvant. Initial screening of mAb activity was
carried out by ELISA: purified hTWEAK was coated onto
96-well plates and various hamster mAbs were tested for
their ability to bind to this immobilized protein. The capture
of hamster mAb was visualized using donkey anti-hamster
IgG (Jackson ImmunoResearch, West Grove, PA, USA)
labelled with horseradish peroxidase. Monoclonal antibod-
ies were further tested to determine whether they were
able to block hTWEAK-flag binding to HT29 cells.
RNA extraction, northern blot analysis and RNAse
protection assay
Total RNA was isolated from cultured cells using TRIzol
reagent (Life Technologies, Paisley, UK) according to sup-
plier’s instructions. RNA was electrophoresed in 1%
formaldehyde agarose gel, transferred to Hybond N nylon
membrane (Amersham, UK) and hybridized to 32P-labeled
MMP-1 (Dr Pierce, St Louis, MO, USA), cyclooxygenase 2
(COX-2) (a gift from Dr PE Poubelle, Ste-Foy, Canada) or
glyceraldehyde-3 phosphate deshydrogenase (GAPDH)
cDNA probes as already described by Rezzonico et al.Arthritis Research    Vol 4 No 2 Chicheportiche et al.
[32]. RNAse protection assay was performed with the
human chemokine multi-probe template set hcK5 from
Pharmingen (San Diego, CA, USA) as described by the
manufacturer.
Determination of IL-8, IL-6, MMP-1, RANTES, IP-10 and
PGE2
Human IL-8 and RANTES were measured by ELISA using
the quantikine immunoassay (R&D, Minneapolis, MN,
USA). Human IL-6 ELISA was performed with innotest hIL-
6 from Innogenetics (Zwijhaarde, Belgium). PGE2 was
quantitized using the products and protocol from Neupert
et al. [33]. The determination of interstitial collagenase
(MMP-1) was carried out as described by Lacraz and col-
leagues [34]. Human IP-10 was measured using Hbt
ELISA (HyCult Biotechnology, Uden, The Netherlands).
Results
Incubation with hTWEAK on dermal fibroblasts and
synoviocytes induces PGE2, MMP-1, IL-8 and IL-6
production
When dermal fibroblasts and synoviocytes were incu-
bated with different concentrations of hTWEAK for 72
hours, PGE2, MMP-1 and IL-8 (and IL-6 to a small extent)
were induced in a dose-dependent fashion (Fig. 1). These
effects were observed in a series of similar experiments
(10 on dermal fibroblasts and four on synoviocytes). As
was to be expected with human pathological specimens,
the basal levels and the increase in production were vari-
able from one cell preparation to the other and differed in
dermal fibroblasts and synoviocytes from different types
of patients and diseases. Of note, tissue inhibitor of met-
alloproteinase-1 was not found to be modulated in
TWEAK-stimulated dermal fibroblasts and synoviocytes
(data not shown).
In the presence of TNF or IL-1β, hTWEAK enhanced two-
to four-fold the production of PGE2, MMP-1 and IL-8
(Fig. 2). Similar results, but less marked, were observed
with synoviocytes (data not shown).
RANTES and IP-10 are strongly induced in dermal
fibroblasts and synoviocytes stimulated by TWEAK
We further analyzed the secretion of proinflammatory mol-
ecules by dermal fibroblasts and synoviocytes by evaluat-
ing the levels of the chemokines RANTES and IP-10 after
stimulation by TWEAK or TNF-α. We observed that these
chemokines were much more strongly induced on dermal
fibroblasts (Tables 1 and 2) and synoviocytes (Table 3)
that had been stimulated by TWEAK than in the presence
of TNF-α; the stimulation index for RANTES and IP-10
being 25 in TWEAK-cultured dermal fibroblasts but only
2.5 and 4 in TNF-cultured dermal fibroblasts. In synovio-
cytes, TWEAK induced RANTES 256-fold and IP-10 19-
fold (compared to TNF-α which induced RANTES 17-fold
and IP-10 6-fold).
Effects of anti-TWEAK mAbs on the secretion of IL-8,
MMP-1, PGE2, IL-6, IP-10 and RANTES by dermal
fibroblasts and synoviocytes stimulated by hTWEAK,
alone or in association with TNF or IL-1β β
The hamster anti-hTWEAK mAbs, BCB10 and BEB3,
were tested for their effects on hTWEAK stimulation of
IL-8, MMP-1, PGE2, IL-6, IP-10 and RANTES production
Figure 1
Stimulation index of dose-dependent induction of IL-8, IL-6, matrix metalloproteinase-1 (MMP-1) and prostaglandin E2 (PGE2) by hTWEAK in 10
experiments on dermal fibroblasts and four experiments on synoviocytes. Polymyxin B-treated cells (2 × 104/well) were incubated for 72 hours in
the presence of human TNF-like weak inducer of apoptosis (hTWEAK) at the indicated doses. Supernatants from dermal fibroblasts or
synoviocytes were tested by ELISA for the different products. Values are shown as mean ± SEM. Except for PGE2, Mann–Whitney P values at 50
ng/ml and at 100 ng/ml versus control were significant (P < 0.02).
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PGE2by dermal fibroblasts. A representative result (out of 3
similar ones) is shown in Table 1. BCB10, a mAb that
inhibits the binding of TWEAK-flag to HT29 cells, totally
blocked the effects of hTWEAK in all the conditions
tested. In contrast, BEB3 in association with hTWEAK
markedly stimulated the production of IL-8 and IL-6
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Figure 2
Stimulation indices of dose-dependent induction of (a) prostaglandin
E2 (PGE2), (b) matrix metalloproteinase-1(MMP-1) and (c) IL-8 by
human TNF-like weak inducer of apoptosis (hTWEAK) in combination
with tumour necrosis factor (TNF) or IL-1β in dermal fibroblasts. Cells
were incubated for 72 hours in the presence of hTWEAK at the
indicated doses, together with TNF (1 ng/ml) or IL-1β (0.1 ng/ml).
Supernatants were analyzed by ELISA for the different products.
Stimulation indices represent TNF plus hTWEAK over control medium
(in grey); IL-1β plus hTWEAK over control medium (in black). Similar
results were obtained in nine independent experiments on dermal
fibroblasts (P < 0.07 for 50 ng/ml hTWEAK compared to control).
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Figure 3
RNAse protection assay on dermal fibroblasts and synoviocytes
stimulated by human TNF-like weak inducer of apoptosis (hTWEAK) or
tumour necrosis factor (TNF) in the presence of anti-TWEAK or anti-
TNF mAbs. Polymyxin B-treated cells were cultured for 16 hours in the
presence of 50 ng/ml TWEAK or 10 ng/ml TNF alone or in association
with 10–7 M of the anti-TWEAK mAbs BCB10 or BEB3 (10 µg/ml) or
anti-TNF mAb (10–7 M). Total RNA was extracted and tested by RNAse
protection assay. Similar results were obtained in four independent
experiments on dermal fibroblasts and two experiments on
synoviocytes. GAPDH, glyceraldehyde-3 phosphate dehydrogenase; 
IP-10, interferon-γ-inducible protein-10; L32, housekeeping gene
present in hcK5 template from Pharmingen; MCP, macrophage
chemoattractant protein, MIP-1α, macrophage inflammatory protein-1α;
RANTES, regulated on activation, normal T expressed and secreted.
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α(18-fold), PGE2 (3.1-fold), MMP-1 (6.7-fold), IP-10 (34-
fold) and RANTES (29-fold). The intrinsic effects of TNF
and IL-1β were not blocked or increased by BCB10 and
BEB3, respectively, indicating that the potentiating effects
of hTWEAK on TNF and IL-1β stimulation were specific.
The synergistic effects of TNF together with TWEAK, as
well as IL-1 together with TWEAK, were dramatic. Indeed,
TNF together with TWEAK increased the production of IP-
10 69-fold and that of RANTES 46-fold, while IL-1
together with TWEAK enhanced RANTES production 35-
fold. BEB3 alone had no effect on the different secretions,
ruling out contamination.
The effects of TWEAK are unaffected by antibodies to
TNF
The use of a blocking mAb to TNF showed that TNF is
not involved in the TWEAK-induced production of IL-8,
MMP-1, PGE2, RANTES and IP-10 in dermal fibroblasts
(Table 2) and in synoviocytes (Table 3). These experi-
ments also revealed that although BEB3 alone had no
effect on control dermal fibroblasts, it induced an
increase in IL-8, MMP-1 and PGE2 secretions with
control synoviocytes.
In synoviocytes, basal levels of IL-8, MMP-1 and PGE2
are decreased by the blocking anti-TWEAK mAb
The anti-TWEAK mAb, BCB10, blocked significantly the
basal secretion of IL-8 and MMP-1. These results, and
those obtained with BEB3, suggest that TWEAK was
endogenous in synoviocyte supernatants.
Effects of anti-TWEAK and anti-TNF mAbs on
chemokine mRNAs induced by TWEAK in human dermal
fibroblasts and synoviocytes.
Dermal fibroblasts and synoviocytes were incubated for
16 hours with hTWEAK, either alone or in association with
the different mAbs. Figure 3 shows that hTWEAK induced
the mRNAs for RANTES, IL-8 and MCP-1 in dermal
fibroblasts. These increases were completely blocked by
BCB10. MMP-1 mRNA (not shown) and the chemokine
mRNAs were further stimulated by BEB3, whereas anti-
TNF mAb did not affect the stimulation by hTWEAK.
Similar results were observed in synoviocytes for IL-8,
MCP-1 and RANTES. Of interest, on synoviocytes, in con-
trast to dermal fibroblasts, hTWEAK was able to increase
macrophage inflammatory protein (MIP)-1α and IP-10
mRNAs. In all the synoviocyte experiments, hTWEAK dif-
Arthritis Research    Vol 4 No 2 Chicheportiche et al.
Table 1
Effects of anti-TWEAK monoclonal antibodies on the secretion of proinflammatory molecules by dermal fibroblasts stimulated by
hTWEAK, alone or in association with TNF or IL-1β β
BCB10 BEB3  Stimulation  BCB10 BEB3  Stimulation 
Stimulus None (10 µg/ml) (10 µg/ml) index* None (10 µg/ml) (10 µg/ml) index*
IL-8 secretion (ng/ml) IL-6 secretion (ng/ml)
Medium alone 6.4 8.3 5.4 1.0 1.1 1.4 0.9 1.0
hTWEAK (50 ng/ml) 55.1 9.6 96.0 17.8 6.0 2.2 15.9 17.7
TNF (1 ng/ml) 111.6 126.1 114.3 1.0 11.2 11.4 10.8 1.0
TNF + hTWEAK 264.3 136.7 446.1 3.9 21.1 13.9 42.9 4.0
IL-1β (0.1 ng/ml) 214.9 248.6 190.2 1.0 42.5 60.9 53.5 1.0
IL-1β + hTWEAK 439.7 277.2 583.1 3.1 69.8 59.3 116.8 2.2
MMP-1 secretion (µg/ml) IP-10 secretion (pg/ml)
Medium alone 0.44 0.53 0.38 1.0 18.5 nd nd 1.0
hTWEAK (50ng/ml) 1.68 0.82 2.46 6.5 388 nd 625 33.8
TNF (1ng/ml) 2.36 2.52 2.49 1.0 241 85 93 1.0
TNF + hTWEAK 2.38 3.09 3.20 1.3 6358 600 6403 68.8
IL-1β (0.1 ng/ml) 2.48 2.82 2.05 1.0 175 103 111 1.0
IL-1β + hTWEAK 3.8 2.89 3.59 1.8 272 83 407 3.7
PGE2 secretion (ng/ml) RANTES secretion (ng/ml)
Medium alone 15 11 10 1.0 0.79 0.63 0.55 1.0
hTWEAK (50 ng/ml) 22 8 31 3.1 10.56 0.77 15.72 28.6
TNF (1 ng/ml) 71 41 57 1.0 2.04 2.65 1.99 1.0
TNF + hTWEAK 125 104 177 3.1 77.88 5.27 91.96 46.2
IL-1β (0.1 ng/ml) 139 156 259 1.0 1.16 1.30 1.49 1.0
IL-1β + hTWEAK 143 186 312 1.2 29.28 1.57 51.78 34.7
* Stimulationindices were calculated from the values obtained with the BEB3 anti-TWEAK mAb results: TWEAK/medium; (TNF + TWEAK)/TNF
alone; (IL-1β + TWEAK)/ IL-1β alone. Similar results were obtained in 3 independent experiments. hTWEAK, human TNF-like weak inducer of
apoptosis; IP-10, interferon-γ-inducible protein-10; MMP-1, matrix metalloproteinase-1; nd, not detectable; PGE2, prostaglandin E2; RANTES,
regulated on activation, normal T expressed and secreted; TNF, tumour necrosis factor.fered markedly from TNF in the chemokine profile induc-
tion since TNF failed consistently to stimulate the expres-
sion of RANTES, IP-10 and MIP-1α mRNAs (Fig. 3).
Discussion
Cultures of human dermal fibroblasts and synoviocytes
have proved relevant to in vitro models for studying surro-
gate markers of the mechanisms of chronic inflammatory
diseases resulting in inflammation and tissue destruction
of the joint structures. Synoviocytes are exquisitely sensi-
tive to mediators of inflammation, such as TNF and IL-1β,
and react strongly to direct contact with inflammatory
T cells [1–6,35]. They are able to secrete numerous pro-
inflammatory molecules, such as PGE2, chemokines (i.e.
IL-8 and MCP-1) and proteolytic enzymes involved in
extracellular matrix destruction such as MMP-1. The home-
ostasis of inflammatory cytokines and metalloproteinases,
as well as their respective inhibitors (i.e. IL-1Ra, TNFsR,
tissue inhibitor of metalloproteinases-1) controls the
process of tissue destruction [3,14,15]. In addition, the
process of repair of collagen and proteoglycan is also
inhibited by IL-1 and TNF [32,35].
We recently reported that a member of the TNF family,
TWEAK, has inflammatory and cytotoxic activities like TNF
and lymphotoxin (LT)α [20]. Marsters et al. [21] have
reported that the receptor for TWEAK is the death-
domain-containing receptor Apo3/DR-3/TRAMP, whereas
Schneider et al. [22] demonstrated that TWEAK-induced
cell death occurs via TNF and TNF receptor I on the
Kym-1 cell line. Nakayama et al. [24] and Kaptein et al.
[36] showed that TWEAK binding and TWEAK-induced
cell death occurs in a number of tumour cells deficient in
Apo3/DR-3/TRAMP. There must exist a TWEAK receptor
that does not contain a death domain because TWEAK
also promotes the growth of endothelial cells [26]. In addi-
tion, in astrocytes, which proved resistant to TWEAK-
induced cell death, the binding of TWEAK results in the
increased secretion of IL-8, IL-6 and intercellular adhesion
molecule [23].
The present study demonstrates another noncytotoxic
effect of TWEAK in that hTWEAK stimulated dermal
fibroblasts and synoviocytes to produce significant
amounts of RANTES, IP-10, IL-8 and MMP-1 as well as
Available online http://arthritis-research.com/content/4/2/126
Table 2
Effects of anti-TWEAK and anti-TNF monoclonal antibodies on the secretion of IL-8, PGE2 and MMP-1 by dermal fibroblasts
stimulated by hTWEAK or TNF
Stimulus None BCB10 (10 µg/ml) BEB3 (10 µg/ml) Anti-TNF (10 µg/ml)
IL-8 secretion (ng/ml)
None 4.9 ± 0.9 5.8 ± 0.6 5.9 ± 0.9 4.6 ± 0.3
hTWEAK (10 ng/ml) 19.8 ± 2.8 6.0 ± 1.2 44.6 ± 6.1 18.8 ± 2.6
TNF(1 ng/ml) 74.3 ± 13 109.3 ± 11 nd 4.5 ± 0.3
MMP-1 secretion (ng/ml)
None 392 ± 17 494 ± 55 523 ± 68 362 ± 32
hTWEAK (10 ng/ml) 789 ± 35 588 ± 8 1287 ± 69 827 ± 21
TNF(1 ng/ml) 2084 ± 154 2863 ± 141 nd 356 ± 37
PGE2 secretion (ng/ml)
None 33 ± 2 24 ± 2 90 ± 6 44 ± 14
hTWEAK(50 ng/ml) 47 ± 4 25 ± 2 103 ± 36 52 ± 10
TNF(1 ng/ml) 190 ± 55 212 ± 75 nd 31 ± 5
RANTES secretion (ng/ml)
None 0.73 0.47 0.72 0.83
hTWEAK(10 ng/ml) 17.22 1.06 47.99 24.96
TNF(1 ng/ml) 1.97 2.20 nd 0.87
IP-10 secretion (pg/ml)
None 82 ± 10 170 ± 40 nd 157 ± 34
hTWEAK(10 ng/ml) 2032 ± 321 217 ± 75 nd 3274 ± 69
TNF(1 ng/ml) 331 ± 57 253 ± 73 nd 78 ± 42
Values for IL-8, matrix metalloproteinase-1 (MMP-1), prostaglandin E2 (PGE-2) and interferon-γ-inducible protein-10 (IP-10) are shown as mean ±
SD; similar results were obtained in 3 independent experiments. Single analyses for RANTES (regulated on activation, normal T expressed and
secreted) were done because the amount of available medium was limited. hTWEAK, human TNF-like weak inducer of apoptosis; nd, not done;
TNF, tumour necrosis factor.some PGE2 and IL-6. Although hTWEAK has proinflamma-
tory properties, these are much less pronounced than
those of IL-1β and TNF (with the exception for RANTES
and IP-10), even though it potentiates the proinflammatory
activities of TNF or IL-1β. In contrast with TNF, induction
by TWEAK of most of the inflammatory mediators requires
a longer time of incubation. Consequently, it cannot be
ruled out that the prolonged effect of TWEAK in stimulat-
ing these mediators may be due to the rapid induction of
one or more intermediate mediators, which are unidenti-
fied to date.
The production of PGE2, MMP-1, IL-8, IL-6, RANTES and
IP-10 induced by hTWEAK (but not the production
induced by TNF and IL-1β) was completely blocked by the
mAb to hTWEAK, BCB10, confirming the specificity of
hTWEAK. Moreover, blocking anti-TNF antibodies were
inactive in the secretion of IL-8, MMP-1, PGE2, RANTES
and IP-10 induced by TWEAK, ruling out any involvement
of TNF in TWEAK activity. In contrast, BEB3, another mAb
to hTWEAK, increased the activity of hTWEAK signifi-
cantly, possibly by promoting the trimerization and/or sta-
bility of TWEAK. Such a mechanism has been observed
with a number of ligands of the TNF family. On synovio-
cytes, but not on dermal fibroblasts, BEB3 alone stimu-
lated the secretion of IL-8, MMP-1 and PGE2, whereas the
blocking mAb to TWEAK, BCB10, reduced the basal level
of IL-8 and MMP-1, suggesting that synoviocytes secrete
endogenous TWEAK. The latency of this activity —
observed on synoviocytes whether stimulated with BEB3
alone or not — could indicate that a soluble TWEAK
inhibitor may also be secreted by these cells. In dermal
fibroblasts, BEB3-crosslinked hTWEAK was shown to
increase the mRNA level of three chemokines of the CXC
or CC families, IL-8, MCP-1 and RANTES. In synovio-
cytes, BEB3-crosslinked hTWEAK increased the mRNA
level of IL-8, MCP-1, RANTES, IP-10 and MIP-1α.The
delayed synthesis of these molecules, contrasting with
TNF-induced stimulation, suggests that TWEAK could be
relevant to the persistence of the inflammatory response
by recruiting neutrophils and macrophages to the site of
the inflammation.
Conclusion
TWEAK may be considered an additional player in the
pathogenesis of chronic immunoinflammatory diseases
leading to tissue destruction. Despite the clearly positive
clinical results, obtained mainly with anti-TNF but to some
Arthritis Research    Vol 4 No 2 Chicheportiche et al.
Table 3
Effects of anti-TWEAK and anti-TNF monoclonal antibodies on the secretion of IL-8, PGE2 and MMP-1 by synoviocytes stimulated
by hTWEAK or TNF
Stimulus None BCB10  (10  µg/ml) BEB3 (10 µg/ml) Anti-TNF (10 µg/ml)
IL-8 secretion (ng/ml)
None 55.2 ± 3.1 38 ± 1.2 117.6 ± 18 49 ± 14
hTWEAK  146.4 ± 17 73 ± 19 277.2 ± 40 113.8 ± 7.3
TNF 232.6 ± 26 245 ± 33 nd 44.7 ± 4.8
MMP-1 secretion (ng/ml)
None 4248 ± 276 3848 ± 371 5383 ± 274 3482 ± 584
hTWEAK 6033 ± 773 4381 ± 22 7923 ± 1698 4878 ± 100
TNF 6197 ± 210 7846 ± 713 nd 3505 ± 101
PGE2 secretion (ng/ml)
None 50 ± 12 61 ± 6 81 ± 13 47 ± 13
HTWEAK 94 ± 7 87 ± 26 161 ± 30 78 ± 3
TNF 231 ± 49 471 ± 79 nd 53 ± 5
RANTES secretion (ng/ml)
None 0.12 0.23 0.23 0.05
hTWEAK 30.78 0.26 20.12 26.01
TNF 2.19 1.17 nd 0.05
IP-10 secretion (pg/ml)
None 274 386 ± 17 349 117 ± 84
hTWEAK 5095 ± 766 330 ± 140 3158 3735 ± 60
TNF 1710 ± 300 1620 ± 20 nd 105
hTWEAK (TNF-like weak inducer of apoptosis) concentration was 10 ng/ml; TNF (tumour necrosis factor) concentration was 1 ng/ml. Values for
IL-8, matrix metalloproteinase-1 (MMP-1), prostaglandin E2 (PGE-2) and interferon-γ-inducible protein-10 (IP-10) are shown as mean ± SD; similar
results were obtained in 3 independent experiments. Single analyses for RANTES (regulated on activation, normal T expressed and secreted) were
done because the amount of available medium was limited. nd, not done.extent also with anti-IL-1 therapy [17,18], as many as 20%
of patients do not respond, while in others the destructive
process persists. It is therefore very likely that other pro-
inflammatory and prodestructive cytokines such as
TWEAK may play an additional or synergistic role in
destructive, chronic inflammatory diseases.
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